

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 JAN 02 STN pricing information for 2008 now available
NEWS 3 JAN 16 CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4 JAN 28 USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5 JAN 28 MARPAT searching enhanced
NEWS 6 JAN 28 USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7 JAN 28 TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8 JAN 28 MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9 FEB 08 STN Express, Version 8.3, now available
NEWS 10 FEB 20 PCI now available as a replacement to DPCI
NEWS 11 FEB 25 IFIREF reloaded with enhancements
NEWS 12 FEB 25 IMSPRODUCT reloaded with enhancements
NEWS 13 FEB 29 WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14 MAR 31 IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15 MAR 31 CAS REGISTRY enhanced with additional experimental spectra
NEWS 16 MAR 31 CA/CAPLus and CASREACT patent number format for U.S. applications updated
NEWS 17 MAR 31 LPCI now available as a replacement to LDPCI
NEWS 18 MAR 31 EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19 APR 04 STN AnaVist, Version 1, to be discontinued
NEWS 20 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS 21 APR 28 EMBASE Controlled Term thesaurus enhanced
NEWS 22 APR 28 IMSRESEARCH reloaded with enhancements

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:33:08 ON 17 MAY 2008

=> file caplus

| COST IN U.S. DOLLARS | ENTRY | SINCE FILE
SESSION | TOTAL |
|----------------------|-------|-----------------------|-------|
| FULL ESTIMATED COST | | 0.21 | 0.21 |

FILE 'CPLUS' ENTERED AT 11:33:26 ON 17 MAY 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 May 2008 VOL 148 ISS 21
FILE LAST UPDATED: 16 May 2008 (20080516/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s (cell-penetrating peptid?)

2393962 CELL

2066630 CELLS

3133503 CELL

(CELL OR CELLS)

26237 PENETRATING

530263 PEPTID?

L1 618 (CELL-PENETRATING PEPTID?)

(CELL(W)PENETRATING(W)PEPTID?)

=> s (sc-fv or scfv or (single chain fv))

50582 SC

3177 SCS

53354 SC

(SC OR SCS)

7672 FV

221 FVS

7765 FV

(FV OR FVS)

8 SC-FV

(SC(W)FV)

4182 SCFV

575 SCFVS

4245 SCFV

(SCFV OR SCFVS)

1418057 SINGLE

3401 SINGLES

1420946 SINGLE

(SINGLE OR SINGLES)

765096 CHAIN

332456 CHAINS

960894 CHAIN

(CHAIN OR CHAINS)

7672 FV

221 FVS

7765 FV

(FV OR FVS)

1711 SINGLE CHAIN FV

(SINGLE(W)CHAIN(W)FV)

L2 4764 (SC-FV OR SCFV OR (SINGLE CHAIN FV))

=> s L1 and l2

L3 2 L1 AND L2

=> d l3 bib abs 1-2

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:972196 CAPLUS

DN 143:244215

TI Penetratin Improves Tumor Retention of Single-Chain Antibodies: A Novel Step toward Optimization of Radioimmunotherapy of Solid Tumors

AU Jain, Maneesh; Chauhan, Subhash C.; Singh, Ajay P.; Venkatraman, Ganesh; Colcher, David; Batra, Surinder K.

CS Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA

SO Cancer Research (2005), 65(17), 7840-7846

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB Single-chain Fv (scFv) antibody

fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides, penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-assocd. glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 h postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, resp., of that accumulated at 8 h postinjection. The tumor-to-blood ratios at 24 h postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, resp., whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiog. of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of s.c.(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:267364 CAPLUS

DN 140:302337

TI Preparation and use of therapeutic antibodies entering into the cell

IN Valkna, Andres; Kogerman, Pritt

PA Inbio Oue, Estonia

SO PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

| PATENT NO. | KIND | DATE | APPLICATION NO. | DATE |
|------------|------|------|-----------------|------|
|------------|------|------|-----------------|------|

| | | | | | |
|---|---|----|----------|-----------------|----------|
| PI | WO 2004026911 | A1 | 20040401 | WO 2003-EE5 | 20030916 |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW | | | | | |
| RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG | | | | | |
| EE | 200200531 | A | 20040415 | EE 2002-531 | 20020917 |
| CA | 2499321 | A1 | 20040401 | CA 2003-2499321 | 20030916 |
| AU | 2003266225 | A1 | 20040408 | AU 2003-266225 | 20030916 |
| EP | 1539823 | A1 | 20050615 | EP 2003-797197 | 20030916 |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK | | | | | |
| US | 20080063633 | A1 | 20080313 | US 2005-528073 | 20050317 |
| PRAI | EE 2002-531 | A | 20020917 | | |
| | WO 2003-EE5 | W | 20030916 | | |
| AB | The disclosed invention relates to the development of a novel technol. of (cancer)-specific antibodies entering into the cell and their use for treatment of human diseases (primarily cancer). Such antibody (drug) would act by directly modulating the cancer-generating signals. The expected effects and principles of action of such antibodies are inactivation of intracellular proteins and thus they could be used for the treatment of diseases, where the activity of intracellular proteins must be modulated for effective treatment (primarily malignant tumors, but also many other diseases, which can be treated by inactivation of intracellular | | | | |

proteins). The invention relates to the use of peptide vector mols. (cell-penetrating peptides, CPPs), preferably peptide transportan (or its shorter analog transportan TP10), a combination of neuropeptide galanin and wasp venom peptide mastoparan fragments. In examples presented here, these CPPs are conjugated to monoclonal (or polyclonal) antibodies to GLI proteins, assocd. with signaling in basal cell carcinoma pathogenesis. These recombinant antibodies were shown to enter the cultured cells. The same results were obtained when the single-chain (scFv) antibody fragments were used in the recombinant protein.

RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (single chain antibody?)

1418057 SINGLE

3401 SINGLES

1420946 SINGLE

(SINGLE OR SINGLES)

765096 CHAIN

332456 CHAINS

960894 CHAIN

(CHAIN OR CHAINS)

329386 ANTIBODY?

L4 2130 (SINGLE CHAIN ANTIBODY?)

(SINGLE(W)CHAIN(W)ANTIBODY?)

=> s L1 and L4

L5 0 L1 AND L4

=> s (single chain antibod?)

1418057 SINGLE

3401 SINGLES

1420946 SINGLE

(SINGLE OR SINGLES)

765096 CHAIN

332456 CHAINS

960894 CHAIN

(CHAIN OR CHAINS)

522810 ANTIBOD?

L6 2550 (SINGLE CHAIN ANTIBOD?)

(SINGLE(W)CHAIN(W)ANTIBOD?)

=> s L1 and L6

L7 1 L1 AND L6

=> d l7 bib abs 1

L7 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:972196 CAPLUS

DN 143:244215

TI Penetratin Improves Tumor Retention of Single-Chain

Antibodies: A Novel Step toward Optimization of Radioimmunotherapy
of Solid Tumors

AU Jain, Maneesh; Chauhan, Subhash C.; Singh, Ajay P.; Venkatraman, Ganesh;
Colcher, David; Batra, Surinder K.

CS Department of Biochemistry and Molecular Biology, University of Nebraska
Medical Center, Omaha, NE, USA

SO Cancer Research (2005), 65(17), 7840-7846
CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB Single-chain Fv (scFv) antibody fragments exhibit improved pharmacokinetics and biodistribution compared with intact IgG. The tumor uptake of scFvs is rapid, and the serum half-life is shorter than IgG. However, scFvs exhibit lower net dose deposition in the tumor due to a shorter residence time that limits their use in radioimmunotherapy. To improve the tumor uptake and retention of scFvs, we investigated the utility of cell-penetrating peptides,

penetratin and transactivator of transcription (TAT). Biodistribution studies were done in LS174T tumor-bearing mice with divalent scFv derived from anti-tumor-assocd. glycoprotein 72 monoclonal antibody (mAb) CC49. Penetratin increased the tumor retention of scFvs without affecting the peak dose accumulation. The percentage of doses retained in tumors at 24 h postadministration with a control (no peptide), penetratin, and TAT were 27.25%, 79.84%, and 48.55%, resp., of that accumulated at 8 h postinjection. The tumor-to-blood ratios at 24 h postadministration were 7.14, 19.53, and 16.48 with control, penetratin, and TAT treatment, resp., whereas the pharmacokinetics were unaltered. Coinjection with TAT, however, resulted in increased uptake of the radioconjugate by the lungs. Autoradiog. of the excised tumors indicated a more homogenous distribution of the radiolabeled scFv with both penetratin and TAT in comparison with the control treatment. Real-time whole-body imaging of the live animals confirmed improved tumor localization with penetratin without any increase in the uptake by normal tissues. In conclusion, a significant improvement in the tumor retention of s.c.(Fv)2 was achieved by administration of penetratin. Therefore, the combination of penetratin and scFvs has the potential of improving the utility of mAb-based radiopharmaceuticals.

RE.CNT 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s (transport peptide)
784339 TRANSPORT
6737 TRANSPORTS
787076 TRANSPORT
(TRANSPORT OR TRANSPORTS)
394289 PEPTIDE
287255 PEPTIDES
503184 PEPTIDE
(PEPTIDE OR PEPTIDES)
L8 331 (TRANSPORT PEPTIDE)
(TRANSPORT(W)PEPTIDE)

=> display history
ENTER (BRIEF), FULL, OR NOFILE:brief
ENTER (L1-), L#, OR ?:L1

(FILE 'HOME' ENTERED AT 11:33:08 ON 17 MAY 2008)

FILE 'CAPLUS' ENTERED AT 11:33:26 ON 17 MAY 2008
L1 618 S (CELL-PENETRATING PEPTID?)

=> se L8 and (sc-fv or scfv or (single chain antibod?))
SE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (>=).

=>

=> s L8 and (scfv or sc-fv or (single chain antibod?))
4182 SCFV
575 SCFVS
4245 SCFV
(SCFV OR SCFVS)
50582 SC
3177 SCS
53354 SC
(SC OR SCS)
7672 FV
221 FVS
7765 FV
(FV OR FVS)
8 SC-FV

(SC(W)FV)
1418057 SINGLE
3401 SINGLES
1420946 SINGLE
(SINGLE OR SINGLES)
765096 CHAIN
332456 CHAINS
960894 CHAIN
(CHAIN OR CHAINS)
522810 ANTIBOD?
2550 SINGLE CHAIN ANTIBOD?
(SINGLE(W)CHAIN(W)ANTIBOD?)
L9 0 L8 AND (SCFV OR SC-FV OR (SINGLE CHAIN ANTIBOD?))

=> s (membrane transport peptide)
792691 MEMBRANE
340529 MEMBRANES
885590 MEMBRANE
(MEMBRANE OR MEMBRANES)
784339 TRANSPORT
6737 TRANSPORTS
787076 TRANSPORT
(TRANSPORT OR TRANSPORTS)
394289 PEPTIDE
287255 PEPTIDES
503184 PEPTIDE
(PEPTIDE OR PEPTIDES)
L10 17 (MEMBRANE TRANSPORT PEPTIDE)
(MEMBRANE(W)TRANSPORT(W)PEPTIDE)

=> s L10 and (scfv or scfv or single chain antibod?)
4182 SCFV
575 SCFVS
4245 SCFV
(SCFV OR SCFVS)
4182 SCFV
575 SCFVS
4245 SCFV
(SCFV OR SCFVS)
1418057 SINGLE
3401 SINGLES
1420946 SINGLE
(SINGLE OR SINGLES)
765096 CHAIN
332456 CHAINS
960894 CHAIN

(CHAIN OR CHAINS)

522810 ANTIBOD?

2550 SINGLE CHAIN ANTIBOD?

(SINGLE(W)CHAIN(W)ANTIBOD?)

L11 0 L10 AND (SCFV OR SCFV OR SINGLE CHAIN ANTIBOD?)